Headlines Covid-19 Specialties Trending Feeds Videos

Mashup Score: 1

Urology Times

The phase 2 HCRN GU16-257 trial explored the bladder-sparing regimen of TURBT plus nivolumab and chemotherapy in patients with muscle-invasive bladder